RecruitingNot ApplicableNCT06664918

Effectiveness and Safety of Milk Ladders in Children with IgE-Mediated Cow's Milk Protein Allergy

Effectiveness and Safety of the 4-Step Versus 6-Step Milk Ladder in Children with IgE-Mediated Cow's Milk Protein Allergy: Protocol for an Open-Label Randomised Controlled Trial


Sponsor

Medical University of Warsaw

Enrollment

92 participants

Start Date

Dec 3, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Cow's milk protein allergy (CMPA) is one of the most common food allergies in early childhood. The first-line treatment of CMPA is the elimination of cow's milk proteins (CMPs) from the child's or maternal diet. Available data from the literature indicate that most children with CMPA acquire tolerance to CMPs with age. An assessment of tolerance acquisition to CMPs is commonly performed using milk ladder. However, scientific evidence regarding the effectiveness and safety of the milk ladder in children with CMPA is limited. Currently, there is no standardised milk ladder protocol, and different versions of the ladder and recommend by scientific societies in various countries. This study aims to assess the effectiveness and safety of the 4-step milk ladder (4-ML) compared to the 6-step milk ladder (6-ML) in children with IgE-mediated CMPA. This is an open-label, randomised superiority trial with two parallel arms and a 1:1 allocation ratio.


Eligibility

Min Age: 1 YearMax Age: 5 Years

Inclusion Criteria8

  • Age between 1 and 5 years.
  • Diagnosis of IgE-mediated CMPA confirmed according to ESPGHAN guidelines, by a positive OFC with CMPs. In high-risk children (i.e., with a history of anaphylaxis), diagnosis based on positive skin prick testing and/or elevated specific IgE to CMPs is sufficient.
  • On a therapeutic elimination diet for at least 6 months or up to 12 months of age.12
  • Eligible regardless of the risk of systemic reaction (anaphylaxis) and asthma.
  • Good overall health status.
  • Parents without language barriers.
  • Written informed consent signed by parents.
  • Good cooperation with the child's guardians.

Exclusion Criteria8

  • Uncontrolled asthma, defined as the presence of shortness of breath, chest tightness, cough, and/or auscultatory changes despite treatment.
  • Signs of exacerbation of a chronic disease.
  • Signs of acute infectious disease (i.e., acute runny nose, cough, subfebrile fever, or fever).
  • Signs of exacerbation of another allergic disease (i.e., conjunctivitis, allergic rhinitis, atopic dermatitis).
  • Anaphylaxis due to CMPs in the last 6 months.
  • Used antihistamines within 3-10 days before the challenge (depending on the characteristics of the drug and the reason for use).
  • Acquired tolerance to baked CMPs or higher steps of the milk ladder.
  • Use of immunosuppressive drugs or immunotherapy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERoral food challenge (OFC)

oral food challenges with subsequent steps of 4-step milk ladder (muffin, pancake,baked hard cheese, yoghurt/pasteurised cow milk or modified cow milk)

OTHERoral food challenge (OFC)

oral food challenges with subsequent steps of 6-step milk ladder (cookie, muffin, pancake,baked hard cheese, yoghurt, pasteurised cow milk or modified cow milk)


Locations(2)

Medical University od Warsaw, Department od Pediatrics

Warsaw, Poland

Medical University od Warsaw

Warsaw, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06664918


Related Trials